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DNA–protein crosslinks are relatively common DNA lesions that
form during the physiological processing of DNA by replication and
recombination proteins, by side reactions of base excision repair
enzymes, and by cellular exposure to bifunctional DNA-damaging
agents such as platinum compounds. The mechanism by which
pathological DNA–protein crosslinks are repaired in humans is not
known. In this study, we investigated the mechanism of recogni-
tion and repair of protein–DNA and oligopeptide–DNA crosslinks
by the human excision nuclease. Under our assay conditions, the
human nucleotide excision repair system did not remove a 16-kDa
protein crosslinked to DNA at a detectable level. However, 4- and
12-aa-long oligopeptides crosslinked to the DNA backbone were
recognized by some of the damage recognition factors of the
human excision nuclease with moderate selectivity and were
excised from DNA at relatively efficient rates. Our data suggest
that, if coupled with proteolytic degradation of the crosslinked
protein, the human excision nuclease may be the major enzyme
system for eliminating protein–DNA crosslinks from the genome.
damage recognition  nucleotide excision repair
DNA–protein crosslinks are intermediates in the reactionpathways of certain enzymes such as integrases, topoisom-
erases, and meiotic recombinases (1–4). In addition, crosslinks
are induced by DNA-damaging agents including ionizing radi-
ation, UV light, metals such as chromium and arsenic (5, 6), and
bifunctional chemotherapeutic drugs such as platinum com-
pounds and nitrogen mustards (7–9). Finally, crosslinks may
form when repair enzymes attempt to process aldehyde groups
either in the DNA backbone in the form of apurinic
apyrimidinic (AP) sites or on oxidized nucleobase residues (10).
The repair of some of these DNA–protein crosslinks is well
understood: the topoisomerase I–DNA 3 tyrosyl-phosphodi-
ester is commonly cleaved in the normal course of the topo-
isomerase (topo) reaction. However, when topo cleaves DNA
near lesions such as pyrimidine dimers or nicks, the enzyme–
DNA crosslink is frozen in transit, giving rise to a stable crosslink
at a single-stranded nick site. This lesion is repaired by a
remarkable enzyme called tyrosyl–DNA phosphodiesterase,
Tdp1 (1). Tdp1 cleaves the 3 tyrosyl-phosphodiester bond and
converts it to a 3 phosphate terminus, which is then processed
to a 3 OH that can be ligated. Tdp1 has also been implicated in
the removal of other 3 adducts (2). The enzyme has been found
in all eukaryotes tested in which a topo I–3 tyrosyl-
phosphodiester bond forms in the course of the reaction but not
in prokaryotes in which the reaction intermediate is a topo
I–DNA 5 tyrosyl-phosphodiester (3).
DNA–protein crosslinks can also form during meiosis. Spo11
in yeast (SPO11 in mammals) makes a staggered double-strand
break to initiate meiotic recombination; each subunit of the
dimeric protein is linked to the resulting 5 ends through a 5
tyrosyl-phosphodiester linkage. In contrast to the topo I–3
tyrosyl-phosphodiester complex, the Spo11–DNA crosslink is
removed by a nuclease that incises the DNA at phosphodiester
bonds 12 or 21–37 nt from the site of the crosslink (4). Genetic
evidence suggests that the incision that releases Spo11 linked to
12 or 21–37 mers is made by the Mre11 subunit of the MRX
(MRN in mammals) complex, and biochemical evidence indi-
cates that the 5 tyrosyl-phosphodiester that forms during ca-
talysis by topo II may be processed by a similar mechanism (4).
Thus, the integrasetopoisomerase I 3 tyrosyl-phosphodiester-
mediated crosslinks are removed by the Tdp1 phosphodiester-
ase, whereas the 5 tyrosyl-phosphodiester-mediated crosslinks
are removed by a nuclease mechanism.
In contrast to these DNA–protein complexes that form either
in the normal course of DNA metabolism or as side products of
DNA processing enzymes, the mechanisms by which other
DNA–protein crosslinks are eliminated are not known (5). Two
potentially abundant lesions in eukaryotic cells are the amide
link between Pol  and 2-deoxy-ribonolactone that is generated
after cleavage of an oxidized AP site by Ape1 (10) and the nitric
oxide-induced deamination of guanine to yield oxanine, which
reacts with the amine groups of any DNA-binding protein to
form an amide bond (11). The natures of many drug-induced
crosslinks can be inferred, although there are only a limited
number of studies on the structures of these lesions (12, 13).
Similarly, there are only a few studies on the repair of these
pathological DNA–protein crosslinks, and these studies have not
provided a unified model. Recently, it was found that the
Escherichia coli nucleotide excision repair enzyme, the (A)BC
excinuclease, can remove a small protein or short oligopeptides
attached to DNA (14, 15). This raises the possibility that
nucleotide excision repair, which is well known for its wide
substrate spectrum (16, 17), may play an important role in
eliminating DNA–protein crosslinks in humans as well.
In this study, we investigated the effect of the mammalian
excision nuclease system on proteins and oligopeptides linked to
the DNA backbone. Under our assay conditions, there was no
detectable removal by the human excision nuclease of T4
endonuclease V [T4 pyrimidine dimer glycosylase (T4-pdg)]
covalently attached to an AP site. However, the excision nucle-
ase system efficiently removed tetra- and dodecapeptides
crosslinked to an AP site. Remarkably, the damage recognition
proteins XPA and XPC were capable of discriminating DNA–
peptide crosslinks from undamaged DNA, albeit with low se-
lectivity. These findings shed some light on the mechanism of
recognition of DNA–protein crosslinks by the human excision
nuclease and suggest that nucleotide excision repair may be a
major contributor to the elimination of these crosslinks, partic-
ularly when the crosslinked protein has been partially degraded
by proteases.
Results
Model Substrates for Repair of DNA–Protein Crosslinks by Human
Excision Nuclease. We used substrates similar to those previously
used for studying repair of these lesions by the prokaryotic
(A)BC excinuclease (Fig. 1). These substrates include a plasmid
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DNA crosslinked at a unique site to T4-pdg and a derivative that
was generated by digesting the plasmid with proteinase K to a
form in which the DNA is crosslinked to the N-terminal amino
acid through a Schiff base formed with the N-terminal residue
of T4-pdg. In addition, we prepared 140-bp duplexes containing
uracil, a reduced AP site, or an AP site crosslinked to T4-pdg,
a tetrapeptide, or a dodecapeptide. All substrates contained 32P
radiolabel at the tenth or sixth phosphodiester bond 5 to the
lesion, as indicated. We also prepared a 136-bp duplex with a
(6-4) photoproduct as a reference substrate for the relative
efficiency of the human excision nuclease on proteinpeptide
crosslinked DNA, because this photoproduct is considered the
‘‘gold standard’’ for the human excision nuclease (16).
Effect of Human Excision Nuclease on a DNA–Protein Crosslink. Al-
though there is no evolutionary relationship between the pro-
karyotic and eukaryotic excision nuclease systems, the two repair
pathways exhibit a convergent reaction mechanism consisting of
low-specificity damage recognition amplified by cooperativity
and kinetic proofreading, helix unwinding by a helicase, and dual
incisions by two separate nucleases (17). Because it has been
shown that the prokaryotic (A)BC excinuclease is capable of
removing crosslinked T4-pdg by the conventional dual incision
mechanism, we reasoned that the six-factor human excision
nuclease (18) may do the same. Fig. 2A shows that, in agreement
with earlier reports, the E. coli (A)BC excinuclease does indeed
release the crosslinked protein attached to an oligomer, pre-
sumably a 12 mer (14, 15). However, when the same or a similar
substrate was incubated with a Chinese hamster ovary (CHO)
extract that is known to be very proficient in nucleotide excision
repair (17), there was no detectable release of an oligonucleotide-
attached protein (Fig. 2B). The excision experiment was carried
out with the six-factor reconstituted human excision nuclease as
well, but under no condition could we detect excision of an
oligonucleotide attached to the protein (Fig. 2B and data not
shown). We reasoned that the failure to excise the crosslink may
be due to the large size of the crosslinked protein that may
interfere sterically with either the assembly or the nucleolytic
attack of the mammalian excision nuclease.
To test this hypothesis, we decided to digest the crosslinked
protein with proteinase K to generate oligopeptides crosslinked
to DNA. Even though we attempted to obtain partial digests that
would retain variously sized fragments of the protein linked to
the DNA by using limiting enzyme concentrations and short
times of incubation, we succeeded only in complete digestion of
the protein. Because the initiator methionine is removed post-
translationally, T4-pdg is crosslinked to DNA at the second
amino acid, threonine. Thus, based on the cleavage specificity of
proteinase K, it is expected that complete digestion would yield
DNA with a single amino acid linked to the DNA backbone.
When this substrate was incubated with CHO cell-free extract,
fragments in the range of 22–34 nt were excised (Fig. 2C),
suggesting that the mammalian excision nuclease is capable of
removing an amino acid linked to the backbone, and that the
failure to remove the T4-pdg crosslink was probably due to the
steric hindrance caused by the size of this protein.
Removal of Tetra- and Dodecapeptide–DNA Crosslinks by Human
Excision Nuclease. The ability of the mammalian excision nuclease
to remove an amino acid–DNA crosslink suggested that the
enzyme may be capable of removing protein–DNA crosslinks as
long as the crosslinked oligopeptide does not cause steric
hindrance for the human excision nuclease. We used a tetra- and
a dodecapeptide that were previously used in studying the
processing of DNA–protein crosslinks by the bacterial excision
nuclease (15). The results are shown in Fig. 3. Both the tetra-
(lane 9) and the dodecapeptide (lane 12) crosslinks are removed
rather efficiently by the human excision nuclease, as evidenced
from a comparison with the excision of the (6-4) photoproduct
(lane 3). Fig. 3 also shows that, in agreement with a previous
report (19), the human excision nuclease removes a reduced AP
site from DNA with relatively good efficiency (lane 6). The
slower migration of excision products of the peptide–DNA
crosslinks relative to other lesions is due to the contribution of
the oligopeptide adducts to the mass of the excised fragment
rather than changes in the size of excised DNA fragments (20).
Recognition of DNA–Peptide Crosslinks by the Damage Recognition
Subunits of Human Excision Nuclease. A number of models have
been put forth for the mechanism of damage recognition by the
human excision nuclease, and attempts have been made to
correlate the selectivity of damage recognition factors with the
efficiency of excision for a specific lesion. In this regard, the
oligopeptide–DNA crosslinks pose an interesting problem.
The particular tetra- and dodecapeptides used in our study are
made up either exclusively (tetrapeptide) or mostly (dodecapep-
tide) of basic and aromatic amino acid residues. It is expected
that these residues will lead to tight binding to DNA through
ionic interactions and intercalation. Depending on the precise
secondary structure of the dodecamer, it is expected to cover a
region of 5 or 12 bp (-helix or -sheet, respectively) around the
crosslink site, and such intimate contact with the DNA might be
expected to interfere with binding by other proteins. However,
that these crosslinks are repaired by the human excision nuclease
indicates that the peptide–DNA crosslinks must be recognized
by the damage recognition factors of the excision nuclease.
Fig. 1. DNA substrates used in repair and DNA-binding assays. (A) Multicloning region of 2.4-kbp pIBI24. The underlined uracil-containing 20 mer was 5
radiolabeled and used in second-strand synthesis to generate a double-strand plasmid for DNA–protein crosslinking. Relevant restriction sites are BamHI (B) and
XhoI (X). (B) The central region of a damaged strand of the 140-bp duplex used for preparation of DNA–protein and –peptide crosslinks. The underlined
uracil-containing 12 mer was 5 radiolabeled. Relevant restriction sites are PvuII (P), HindIII (H), and SalI (S). (C) Central region of damaged strand of the 136-bp
duplex used as a control substrate. The underlined 8 mer containing T[6-4]T photoproduct was 5 radiolabeled. Relevant restriction sites are as in B. In B and C,
numbers above 5 and 3 bars indicate distances to 5 and 3 termini, respectively. The uracil was removed by uracil DNA glycosylase to generate an AP site,
indicated by an ‘‘O.’’








Therefore, we carried out electrophoretic mobility-shift assays to
assess the recognition of peptide–DNA crosslinks by the RPA,
XPA, and XPC subunits that are known to confer specificity to
the human excision nuclease enzyme. The approximate binding
dissociation constants (Kd(app)) for these repair factors are
summarized in Fig. 4. It must be noted that these values reflect
the binding affinity of factors to a 52-bp duplex containing the
indicated structures without appropriate corrections for the
increase in affinity conferred by a single damaged base and are
meant only as indicators of relative affinities of the repair factors
to the various lesions. Of interest, we find that XPA discriminates
more efficiently between the tetrapeptide crosslink and undam-
aged DNA, whereas XPC discriminates better between the
dodecapeptide crosslink and undamaged DNA. However, it
must be noted that there is considerable variability in the binding
affinities of these proteins depending on the enzyme batch and
binding conditions. The only statement that can be made with
relative certainty is that the (6-4) photoproduct, the ‘‘gold
standard’’ of the human excision nuclease, is recognized effi-
Fig. 2. Excision of DNA–protein crosslinks by E. coli and human excision
nucleases. (A) Duplex (140 bp) containing T4-pdg crosslinked to a unique AP
site (0.6 nM) was incubated with 50 nM UvrA, 200 nM UvrB, and 200 nM UvrC
for 60 min at 30°C, as indicated. SDSPAGE loading buffer was added to
reaction mixtures that were heated 5 min at 37°C before resolution by 12%
SDSPAGE. The closed arrow to the right identifies the band corresponding to
excision product. (B) pIBI24 containing T4-pdg crosslinked to a unique AP site
was incubated without (lane 1) or with 50–60 g of extracts prepared from
wild-type CHO cells (WT, AA8), XP-G mutant CHO cells (UV135), mutant extract
complemented with XPG protein (XP-G  XPG), and HeLa cells for 60 min at
30°C (lanes 2–5). SDSPAGE loading buffer was added to reaction mixtures
that were heated 5 min at 95°C before resolution by 12% SDSPAGE. Marker
(M) DNA was generated by BamHI  XhoI digestion of the substrate: T4-pdg
crosslinked to 29 mer is approximately the size of the predicted excision
product. (C) Effect of human excision nuclease on amino acid–DNA crosslink.
pIBI24–T4-pdg DNA was treated with proteinase K to generate a plasmid
containing a crosslinked amino acid (pIBI24–AA). DNA (0.3 nM) was incubated
with XP-G mutant CHO cell extract (UV135) or CHO-UV135 extract comple-
mented with recombinant XPG for 60 min at 30°C. Bracket indicates excision
products (13.5% of the substrate). Lane 3 (M) is pIBI24–AA digested with
BamHI  XhoI to release a 29 mer containing the damage; this species migrates
as a 31 mer, and faster-migrating species are reduced AP site 29 mer and
fragments resulting from digestion of incomplete ligation products.
Fig. 3. Excision of DNA–peptide crosslinks by human repair factors. Substrate
DNA (0.4 nM) was incubated with RPA (140 nM), XPA (65 nM), XPChR23B (5
nM), TFIIH (12 nM), and XPFERCC1 (4 nM) in the absence or presence of XPG
(3 nM) for 90 min at 30°C. DNA alone (all repair factors omitted, lanes 1, 4, 7,
and 10), reactions lacking XPG (lanes 2, 5, 8, and 11), and complete reactions
(lanes 3, 6, 9, and 12) are shown for T[6-4]T photoproduct (lanes 1–3), reduced
AP site (RAP, lanes 4–6), DNA–KWKK crosslink (PEP4, lanes 7–9), and DNA–
KFHEKHHSHGRY crosslink (PEP12, lanes 10–12). Brackets indicate excision
products visualized by autoradiography after resolution in 10% sequencing
gel. Two brackets are shown in lane 12: the PEP12 substrate contained 75%
crosslinked peptide and 25% RAP, and excision of the latter lesion resulted in
release of products that comigrated with those shown in lane 6. For lanes 1–3,
50% of the recovered DNA was resolved in this gel. Levels of excision were
36% for T[6-4]T (lane 3), 11% for RAP (lane 6), 9% for PEP4 (lane 9), 11% for
PEP12 (lane 12), and 9% for RAP (lane 12).
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ciently by all damage recognition factors with higher selectivity
than the DNA–oligopeptide crosslinks.
Then, we conducted kinetic experiments to determine the
relative proficiencies of the DNA–peptide crosslinks as sub-
strates for the mammalian excision nuclease and to find out
whether there is a correlation between recognition efficiencies
by individual repair factors and the rates of excision by the
excision nuclease. Reduced AP site DNA was not analyzed in
these kinetic experiments, because excision of this lesion was not
observed with CHO cell extracts (data not shown), presumably
because base excision repair enzymes in the extracts avidly bind
the reduced AP site and exclude RPA, XPA, and XPC from the
damage site. The results are shown in Fig. 5. The (6-4) photo-
product is repaired at a faster rate than the tetra- and dode-
capeptide crosslinks that are repaired with comparable efficien-
cies by the mammalian excision nuclease. Whether there is a
correlation between the recognition specificity and excision
efficiency cannot be ascertained from our data, because the
discrimination by all three repair factors between damaged and
undamaged DNA is rather poor. As reported elsewhere, we
believe that the human excision nuclease achieves high specific-
ity mainly by a kinetic proofreading mechanism (21, 22).
Discussion
A number of studies have shown that both ‘‘spontaneous’’ and
radiation- and chemical-induced DNA–protein crosslinks are
rather common lesions, but the repair of these lesions has not
been investigated in a systematic manner. DNA–protein
crosslinks may be classified into several classes. First, the protein
may be linked to the phosphodiester backbone at a nick (topo I
and Pol ) or a double-strand break (topo II and Spo11) (1–4,
10). Second, the protein may be crosslinked to an oxidized base
as in the case of T4-pdg, and presumably the crosslinks that are
formed by ionizing radiation and oxidative stress (5, 6, 12, 13).
Third, the protein may be crosslinked to the base, as occurs with
the nitrosative deamination product of guanine, oxanine, which
reacts with amino groups of DNA-binding proteins (11). Simi-
larly, many bifunctional chemotherapeutic drugs such as plati-
num compounds and nitrogen mustards react with amino groups
of DNA bases and amino acids of DNA-binding proteins to
generate crosslinks (7–9).
Because crosslink-inducing agents also generate simple base
and backbone lesions, the contributions of DNA–protein
crosslinks to lethality caused by agents such as UV and ionizing
radiation, platinum compounds, and nitrogen mustards are not
known. For the same reasons, it has been difficult to genetically
analyze the contributions of various enzyme systems to removal
of crosslinks. In vivo biochemical analyses in favor of and against
involvement of nucleotide excision repair in crosslink removal
after treatment with transplatinum or formaldehyde have been
published, but these studies are inconclusive (23–28) and in
general conclude that multiple repair pathways may be involved.
There is a report that a histone H1–DNA crosslink is not excised
in vitro by a mammalian repair system, but it is possible that the
inability to detect excision was due to the insufficient sensitivity
of the assay system (9). Recently, it was found that the bacterial
Fig. 4. DNA binding by RPA, XPA, and XPC. Substrate DNA (0.05 nM) was
incubated with increasing amounts of RPA (50–200 nM), XPA (25–200 nM), or
XPC (2–10 nM) in the presence of 0.1 nM undamaged DNA. Binding was
analyzed by electrophoretic mobility-shift assay and quantified by Phosphor-
Imager analysis. Approximate Kd(app) values were estimated by visual exami-
nation of binding isotherms to determine the concentration (nM) at which
50% substrate was bound. UM, unmodified; 6–4PP, T[6-4]T photoproduct;
PEP4, DNA–KWKK crosslink; PEP12, DNA–KFHEKHHSHGRY crosslink.
Fig. 5. Kinetics of excision by CHO cell-free extracts. Substrates (0.5 nM) were
incubated at 30°C with 50 g of XP-G (UV135) cell extract complemented with
15 ng of recombinant XPG. Aliquots were removed at 15-, 30-, 60-, and 90-min
time points, deproteinized, and precipitated with ethanol. Recovered DNA
was resolved in 10% sequencing gel, visualized by autoradiography, and
quantified by PhosphorImager analysis. (A) Autoradiogram of representative
experiment; only the bottom segment of the autoradiogram is shown. Sub-
strates were DNA–KWKK crosslink (PEP4, lanes 1–5), DNA–KFHEKHHSHGRY
crosslink (PEP12, lanes 6–10), and T[6-4]T photoproduct (lanes 11–15). Num-
bers to the right indicate size (in nucleotides) at which the largest major
excision product migrated: 41 (PEP12), 36 (PEP4), and 29 (T[6-4]T). (B) Quan-
titative analysis of excision. Average values of excision from results shown in
A and a second experiment performed under the same conditions are plotted.
Triangles, T[6-4]T; squares, PEP12; circles, PEP4.








(A)BC excinuclease can remove oligopeptides and a small
protein crosslinked to DNA by the conventional dual incision
mechanism (14, 15). Similarly, a recent study demonstrated that
both human and bacterial excision nucleases can remove an
oxanine–spermine adduct with modest efficiency, suggesting
that the human enzyme like the bacterial excision nuclease may
repair DNA–protein crosslinks as well (29).
In the present study, we were unable to detect excision of
T4-pdg–DNA crosslinks by the human excision nuclease. During
the repair reaction, there are intimate contacts between the
damage recognition subunits of the human excision nuclease and
the damaged bases (30), and an essential early step of repair is
the unwinding of an 20-bp region of the duplex (31). T4-pdg
asymmetrically contacts both strands in the vicinity of a thymine
dimer (32, 33) and thus may interfere with binding of damage
recognition subunits as well as preventing unwinding of the
duplex by TFIIH or blocking access of the XPG and
XPFERCC1 nucleases to DNA (16, 17). It is possible that such
interference is true for other DNA-binding proteins that may be
crosslinked to DNA after exposure to damaging agents. There-
fore, we suspect that the inefficient (or lack of) repair of the
T4-pdg–DNA crosslink may be due to steric hindrance by this
16-kDa protein, and that such crosslinks may be eliminated after
proteolytic processing. With that in mind, we decided to test
proteolytic products of T4-pdg–DNA crosslinks and the tetra-
and dodecapeptide crosslinks as substrates. We find that both the
former (which is presumably a single amino acid crosslink) and
the latter are repaired rather efficiently. In fact, the rates of
repair of these crosslinks are more efficient than that of the
cyclobutane pyrimidine dimer, the classical substrate for the
human excision nuclease. Whether the in vitro repair of DNA–
peptide crosslinks has any bearing on the in vivo repair of
DNA–protein crosslinks remains to be determined. There are
suggestions that DNA–protein crosslinks, whether generated by
exogenous agents or by DNA processing enzymes, are processed
by proteasomes (1, 15, 28, 34, 35). If proteasome-mediated
degradation of crosslinked proteins occurs to a significant de-
gree, then the DNA–peptide crosslink removal activity of the
human excision nuclease described in this work may constitute
an essential step in eliminating crosslinks induced by oxidative
and nitrosative stress and chemotherapeutic drugs.
Materials and Methods
Preparation of DNA Substrates. Three types of substrates were
prepared as described (36): (i) A 2.4-kbp plasmid, pIBI24,
containing a single uracil residue in the multiple cloning site; (ii)
136- or 140-bp duplexes with centrally located uracil or UV-
induced T[6–4]T photoproduct; and (iii) 52-bp duplexes that
were derived from 136- or 140-bp duplexes (Fig. 1). Single-
stranded pIBI24 was used for second-strand synthesis with a
20-nt oligonucleotide radiolabeled at the 5 end to obtain a
circular duplex with a uracil residue at a unique position. The
136- and 140-bp duplexes were assembled by annealing and
ligation of six complementary and partially overlapping oli-
gomers. The 52-bp duplexes with 5-nt tails on the undamaged
strand were generated by PvuII  SalI digestion of the 136- or
140-bp duplexes (Fig. 1 B and C). Oligonucleotides were ob-
tained from Operon Technologies (Alameda, CA) or were
prepared in house (36, 37).
DNA oligonucleotides (140-bp duplexes) and plasmid DNA
containing a single uracil residue (Fig. 1) were treated with
catalytic amounts of uracil DNA glycosylase (Trevigen, Gaith-
ersburg, MD) to generate substrates containing site-specific AP
sites 6–10 nt 3 to the radiolabel; completion of the reaction was
monitored by treatment with T4-pdg (Trevigen). To generate a
site-specific crosslink, a molar excess of T4-pdg was incubated
with AP DNA, as described (14). For the 140-bp duplex, 250
fmol AP DNA was incubated with 60–70 pmol T4-pdg and 50
mM NaBH4 for 15 min at 22°C in 100-l reactions. The efficiency
of crosslinking was typically 50%, as determined by Phosphor-
Imager analysis after SDSPAGE, and the crosslinked DNA was
purified from polyacrylamide gels as described (14). During the
purification steps, a significant portion of the substrate failed to
elute from the gel(s), and what did elute was contaminated with
faster-migrating species of ill-defined origin. This linear sub-
strate was used for (A)BC excinuclease reactions, but the
contaminants precluded using this substrate with the mamma-
lian system. For the mammalian excision nuclease, we used
plasmid DNA as substrate. The substrate was prepared by
incubating 5 pmol pIBI24–AP DNA with 480 pmol T4-pdg and
100 mM NaBH4 for 15 min at 22°C in 500-l reactions. The
reactions were quenched by adding NaCl to 250 mM and holding
on ice 1 h. Microcon 30 devices (Amicon) were used to
concentrate the DNA and exchange the crosslinking buffer with
a buffer containing 30 mM Hepes, pH 7.9, 40 mM KCl, 3.2 mM
MgCl2, and substrates were stored at 4°C. Efficiency of crosslink-
ing was assessed by digesting an aliquot with BamHI  XhoI to
release a 29 mer crosslinked to the protein (Fig. 1 A). Crosslink-
ing efficiency was typically 70%.
The DNA–amino acid crosslink substrate was prepared by
proteinase K digestion of pIBI24–T4-pdg substrates followed by
purification on Sepharose CL-4B columns after adding PMSF to
10 mM. Substrates were recovered after ethanol precipitation.
The tetra- and dodecapeptides, PEP4 (KWKK) and PEP12
(KFHEKHHSHGRY), were synthesized at the Microprotein
Sequencing and Peptide Synthesis Facility (University of North
Carolina, Chapel Hill), resuspended in 20% acetonitrile, and
used for preparation of 140 mers containing site-specific peptide
crosslinks as described (15). The tetrapeptide crosslinking reac-
tion was essentially complete, and dodecapeptide crosslinking
efficiency was typically 75%. Reduced AP site substrates were
prepared by treating the AP–DNA with NaCNBH3 in the
absence of peptide. Substrates were recovered after ethanol
precipitation and stored at 20°C in 50 mM Tris, pH 7.9100
mM NaCl10 mM MgCl21 mM DTT.
Cell-Free Extracts and Purified Repair Factors. CHO AA8 (wild type)
and UV135 (XP-G mutant) and HeLa cell-free extracts were
prepared as described (36). The three E. coli repair factors,
UvrA, UvrB, and UvrC, and the six factors of the human excision
nuclease, RPA, XPA, XPChR23B, TFIIH, XPFERCC1, and
XPG, were purified and stored as described (36).
Analysis of Nucleotide Excision Repair and DNA Binding. Excision by
the bacterial repair system was monitored by incubating UvrA,
UvrB, and UvrC with substrate DNA at the indicated concen-
trations in a standard reaction mixture (36). Excision repair
assays with CHO cell-free extracts were performed at 30°C by
using a standard reaction buffer (36) containing 5- to 15-fmol
radiolabeled substrate and 50–60 g of extract. Where indicated,
mutant cell extracts were supplemented with the missing repair
factor. For kinetic assays, the reaction mixture was scaled up, and
aliquots were removed at the indicated time points. Excision
assays with the six-factor human excision nuclease were per-
formed as described (36) with 4–5 fmol substrate and the
indicated amounts of repair factors.
To analyze excision products of T4-pdg-crosslinked substrates,
reactions were stopped by addition of SDSPAGE loading
buffer. Samples were resolved in 12% polyacrylamide-SDS gels
and visualized by autoradiography. Reactions with crosslinked
oligopeptides and other substrates were terminated by addition
of SDS to 0.35% and incubation for 30 min at 65°C followed by
phenol and phenol:chloroform extractions. DNA was recovered
after ethanol precipitation, resuspended in formamidedye mix-
ture, and resolved in 10% sequencing gels. Excision was visual-
ized by autoradiography, and percentage excision was quantified
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by using a PhosphorImager (Storm 860) and IMAGEQUANT
program (GE Healthcare). Excision levels for each reaction were
determined as a percentage of radiolabel in the excision product
region of the gel relative to the total radiolabel in the substrate
migrating at 136 or 140 nt plus excision products in that lane.
DNA-binding reactions (12.5 l) were performed in buffer
containing 50 mM Tris (pH 8), 60 mM KCl, 5 mM MgCl2, 10%
glycerol, 0.05 nM substrate DNA, and increasing amounts of
RPA, XPA, or XPC (4 l of protein diluted in 25 mM Hepes, pH
7.9100 mM KCl12 mM MgCl20.5 mM EDTA2 mM DTT
12.5% glycerol). After a 30-min incubation at 30°C, samples were
resolved in 5% polyacrylamide gels, visualized by autoradiogra-
phy, and percentage bound was quantified by using a Phosphor-
Imager and IMAGEQUANT program.
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